New MannKind Data Appear Positive, But Doubts Persist About Afrezza's Viability
This article was originally published in The Pink Sheet Daily
Executive Summary
Pulmonary function data don't resolve questions about safety, analysts argue.
You may also be interested in...
MannKind Gears Up To Make Commercial Case For Inhaled Insulin Afrezza
With two new positive Phase III studies, MannKind is getting back on regulatory track, with plans for a new FDA filing of Afrezza in the fourth quarter. Still, the firm is planning more Phase IIIb/Phase IV studies to differentiate the inhaled insulin on the market.
MannKind Gears Up To Make Commercial Case For Inhaled Insulin Afrezza
With two new positive Phase III studies, MannKind is getting back on regulatory track, with plans for a new FDA filing of Afrezza in the fourth quarter. Still, the firm is planning more Phase IIIb/Phase IV studies to differentiate the inhaled insulin on the market.
MannKind Gears Up To Make Commercial Case For Inhaled Insulin Afrezza
With two new positive Phase III studies, MannKind is getting back on regulatory track, with plans for a new FDA filing of Afrezza in the fourth quarter. Still, the firm is still planning more Phase IIIb/Phase IV studies to differentiate the inhaled insulin on the market.